Author： Hwang Pai-An Lin Xiao-Zhen Kuo Ko-Liang Hsu Fu-Yin
Publisher： MDPI
E-ISSN： 1996-1944|10|3|291-291
ISSN： 1996-1944
Source： Materials, Vol.10, Iss.3, 2017-03, pp. : 291-291
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Fucoidan, an anionic, sulfated polysaccharide from brown seaweed, is known to exhibit antitumor and immunomodulatory functions. To develop an immune protection and chemotherapeutic agent, fucoidan-cisplatin nanoparticles (FCNPs) were designed. FCNPs were prepared by mixing cisplatin with fucoidan solution or fucoidan with cisplatin solution, followed by dialysis to remove trace elements. The nanoparticles, comprising 10 mg of fucoidan and 2 mg of cisplatin, which exhibited the highest cisplatin content and loading efficiency during the production process, were named as Fu100Cis20. The cisplatin content, cisplatin loading efficiency, nanoparticle size, and zeta potential of Fu100Cis20 were 18.9% ± 2.7%, 93.3% ± 7.8%, 181.2 ± 21.0 nm, and −67.4 ± 2.3 mV, respectively. Immune protection assay revealed that Fu100Cis20-treated RAW264.7 cells were protected from the cytotoxicity of cisplatin. Furthermore, antitumor assay indicated that Fu100Cis20-treated HCT-8 cells showed stronger cytotoxicity than those treated with cisplatin alone. These results suggested that fucoidan-based nanoparticles exhibited suitable particle size and high drug encapsulation, and that Fu100Cis20 has potential application in both immunotherapy and chemotherapy.
Related content
By Zhan Zhengwen Zhang Xiaoxu Huang Jiayuan Huang Ying Huang Zhengwei Pan Xin Quan Guilan Liu Hu Wang Lili Wu Chuanbin
Materials, Vol. 10, Iss. 7, 2017-06 ,pp. :
Access to resources
Recommend
By Szymonowicz Maria Korczynski Mariusz Dobrzynski Maciej Zawisza Katarzyna Mikulewicz Marcin Karuga-Kuzniewska Ewa Zywicka Boguslawa Rybak Zbigniew Wiglusz Rafal J.
Materials, Vol. 10, Iss. 6, 2017-05 ,pp. :
Access to resources